MARKET

CDXS

CDXS

Codexis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.74
-0.01
-0.04%
Opening 11:49 09/16 EDT
OPEN
24.71
PREV CLOSE
24.75
HIGH
25.13
LOW
24.44
VOLUME
63.92K
TURNOVER
--
52 WEEK HIGH
29.56
52 WEEK LOW
11.48
MARKET CAP
1.60B
P/E (TTM)
-65.9382
1D
5D
1M
3M
1Y
5Y
Baillie Gifford Global Stewardship Equities Fund Buys 10x Genomics Inc, NIBE Industrier AB, ...
GuruFocus News · 2d ago
Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin
Benzinga · 6d ago
Codexis, Merck Amend And Extend Supply Agreement For Enzyme Used In Manufacture Of Sitagliptin
Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and
Benzinga · 6d ago
Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences.
GlobeNewswire · 09/07 20:05
Return on Capital Employed Insights for Codexis
After pulling data from Benzinga Pro it seems like during Q2, Codexis's (NASDAQ:CDXS) reported sales totaled $25.45 million. Despite a 51.0% in earnings, the company posted a loss of $4.49 million.
Benzinga · 08/31 15:37
BRIEF-Codexis Confirms Receipt Of Follow-On Orders For Proprietary Enzyme Product From Undisclosed Global Pharmaceutical Co
reuters.com · 08/25 20:30
Codexis Confirms Receipt of $15M Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company
Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received new purchase orders with an aggregate total value of approximately $15 million
Benzinga · 08/25 20:13
Codexis Secures Purchase Orders for Enzyme Product
MT Newswires · 08/25 17:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDXS. Analyze the recent business situations of Codexis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDXS stock price target is 29.50 with a high estimate of 34.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 63.88M
% Owned: 98.83%
Shares Outstanding: 64.64M
TypeInstitutionsShares
Increased
59
4.00M
New
15
504.13K
Decreased
44
1.42M
Sold Out
22
1.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
President/Chief Executive Officer/Director
John Nicols
Chief Financial Officer/Senior Vice President
Ross Taylor
Independent Director
Jennifer Aaker
Independent Director
Stephen Dilly
Independent Director
Byron Dorgan
Independent Director
Esther Martinborough
Independent Director
Alison Moore
Independent Director
David Smith
Independent Director
Dennis Wolf
Independent Director
Patrick Yang
No Data
About CDXS
Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Webull offers kinds of Codexis, Inc. stock information, including NASDAQ:CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.